XOMA RoyaltyXOMA 45 FCF Yield % is 0.91 as of Jun. 30, 2026. GuruFocus rates XOMA with a GF Score™ of 45/100 and a GF Value™ of $18.85 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,415 Biotechnology companies, XOMA Royalty ranks better than 85.44% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
XOMA Royalty FCF Yield % Related Terms
XOMA Royalty FCF Yield % Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XOMA Royalty's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's FCF Yield % distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA Royalty (XOMA) has a FCF Yield % of 0.91 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XOMA Royalty and its competitors. According to the industry distribution chart, XOMA Royalty ranks #206 out of 1415 companies in the Biotechnology industry, placing it in the top 14.6%.
Is XOMA Royalty's FCF Yield % too high?
XOMA Royalty's current FCF Yield % is 0.91. Based on the distribution chart, XOMA Royalty ranks #206 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's FCF Yield % compare to CLYM and CTMX?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #206 out of 1415 companies for FCF Yield %. This places XOMA Royalty in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current FCF Yield % is 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.85, compared to a current price of $42.15 — trading 123.6% above its estimated fair value. The current FCF Yield % is 0.91. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current FCF Yield % is 0.91 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $42.15 is trading 123.6% above its estimated GF Value™ of $18.85.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
FCF Yield %: 0.91
GF Value™: $18.85 vs. price of $42.15 (123.6% above fair value)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score
Get the complete analysis for XOMA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
